Locations
San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series B
founded in
2016
Candesant Biomedical, Inc. is a medical device company focused on developing a novel treatment for excessive sweating or hyperhidrosis. Their lead product, The Brella® Sweat Control Patch, is a non-invasive topical patch that provides a quick, in-office procedure to treat excessive sweating. The technology, known as Targeted Alkali Thermolysis (TAT), effectively inactivates sweat glands and has shown significant sweat reduction benefits lasting up to 3-4 months after a single treatment. Candesant aims to improve the quality of life for the 84 million people in the U.S. who suffer from excessive sweating, positioning itself as a leader in this niche market with a strong clinical validation of its product.
Something looks off?